The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbs
Manali Kamdar, MD, University of Colorado, Aurora, CO, comments on third-line treatment options for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Kamdar explains that whilst CAR-T therapy has transformed the treatment landscape for these patients, there remains an unmet need for patients who relapse after CAR-T or who are ineligible for this treatment. Options including CD20-directed bispecific antibodies like epcoritamab, antibody-drug conjugates (ADCs) like loncastuximab tesirine, and the combination of tafasitamab and lenalidomide represent promising options in this setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
